EGFR and cancer: Immune checkpoint inhibitors (ICIs) and anti-PD-1/PD-L1 monoclonal antibodies inhibit the interaction of PD-1 with their ligands, hence promoting an immunologic response by T cells against cancer cells, which failed to prove its efficacy as mono-therapy in patients harboring EGFR-sensitive mutations after resistance (17).